At Alnylam, we want to understand your journey, your experiences, and your unique needs. You inspire us to learn as much as we can, to persevere and continue to advance the development of potential therapies to treat rare and serious diseases. We take pride in working together to achieve mutual goals such as increasing awareness, enabling diagnosis, and providing education and services to support patient communities. We have a dedicated team to ensure your perspectives are represented at Alnylam. If you are an advocate interested in helping us increase awareness of rare diseases, please send an email to PatientAdvocacy@alnylam.com
RNA interference (RNAi) is the core discovery that forms the therapies Alnylam is developing. It is recognized as a major scientific breakthrough—but how does it work, exactly?
Learn about RNAi and our investigational therapies
Alnylam is focused on 4 Strategic Therapeutic Areas (STArs): genetic medicines, cardio-metabolic diseases, infectious diseases, and central nervous system (CNS) and ocular diseases
Alnylam is dedicated to providing support for affected individuals, families, and caregivers
Alnylam Assist® offers patients personalized support throughout their treatment with an Alnylam product.
Visit Site ›
Through Alnylam Act®, healthcare professionals can request genetic testing and counseling for hATTR amyloidosis, acute hepatic porphyria, or primary hyperoxaluria type 1 for individuals meeting certain criteria.
RNAi is a breakthrough in the understanding of how genes are regulated in cells.